Top of this page
Skip navigation, go straight to the content

Investors UCB equity story

Since 2015, UCB has embarked on a very important change journey:

the Patient Value Strategy

In 2019 we entered the next phase of our Patient Value Strategy:

“Accelerate & Expand” (2019-2022)

 

 
During this phase, we are accelerating our growth potential by further improving our ability to demonstrate differentiation of our medicines, by accelerating our development timelines through new approaches and by improving patients’ access to our key medicines.
Based on our strong clinical development pipeline, we have the potential for 6 new product launches* by 2025.

 
 

Up to 7 potential product launches* by 2025

  • Romosozumab in severe osteoporosis
  • Midazolam nasal spray in acute repetitive epilepsy seizures
  • Bimekizumab in psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa 
  • Rozanolixizumab in Immune ThrombocytoPenia, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy 
  • Zilucoplan in general Myasthenia Gravis
  • Padsevonil in drug-resistant epilepsy  
  • Anti-Tau in progressive supranuclear palsy

 

* subject to approval

In 2019, we made significant progress towards this ambitious goal

  • Evenity® (romosozumab) and Nayzilam® (midazolam) were approved and launched as planned.
  • bimekizumab delivered three positive Phase 3 study results in psoriasis; submission to regulatory bodies should occur  mid-2020.
  • UCB started multiple Phase 3 studies: bimekizumab in psoriatic arthritis, axial spondyloarthitis and hidradenitis suppurativa (early 2020), padsevonil in drug resistant epilepsy and rozanolixizumab in generalized myasthenia gravis as well as in immune thrombocytopenia.
  • UCB0107, our anti-Tau antibody, reported positive Phase 1 results and will enter the confirmatory study in Q2 2020.
 

Our key medicines

We bring solutions to people living with neurological or immunological diseases.

Serving patients, our key medicines continued their growth in 2019.

Immunology

Cimzia

Peak sales guidance

 

  • Cimzia® > € 2 billion by 2024  
  • Vimpat® > € 1.5 billion by 2022  
  • Briviact® > € 600 million by 2026
  • Neupro® ~ current level  
 
Keppra® reached peak sales of € 1.2 billion in 2008.

Neurology

Vimpat

 

Keppra logo

Neupro

Our pipeline

In a challenging environment, our pipeline builds the basis of UCB’s sustainable long term growth.

To create a pipeline that will make a real difference in people’s lives, we focus on our key assets: our expertise in small and large molecules and our expertise in the fields of neurology and auto-immune diseases.

Up to 7 potential product launches* by 2025

  • Romosozumab in severe osteoporosis (launched in 2019)
  • Midazolam nasal spray in acute repetitive epilepsy seizures (launched in 2019)
  • Bimekizumab in psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa
  • Rozanolixizumab in Immune ThrombocytoPenia, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy 
  • Zilucoplan in general Myasthenia Gravis
  • Padsevonil in drug-resistant epilepsy  
  • Anti-Tau in progressive supranuclear palsy

 

* subject to approval

Clinical studies index

UCB is committed to sharing information on studies and making study results publicly accessible. You will find below links to the clinical studies (Phase 2-4) of our main R&D projects.

More information about our clinical studies index and our position paper are available here.

 
 
 
 

UCB pipeline

February 2020

CIDP: Chronic Inflammatory Demyelinating Polyneuropathy

 

Newsflow since February 2020:

 

 

Questions?

Contact the IR team and we will do our best to help you!